Vanderbilt University School of Medicine, 1161 21st Ave S # D3300, Nashville, TN, 37232, USA.
Surgical Outcomes Center for Kids, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, USA.
Transl Stroke Res. 2022 Feb;13(1):46-55. doi: 10.1007/s12975-021-00896-3. Epub 2021 Feb 21.
This study measures effect of CYP2C19 genotype on ischemic stroke risk during clopidogrel therapy for asymptomatic, extracranial carotid stenosis patients. Using deidentified electronic health records, patients were selected for retrospective cohort using administrative code for carotid stenosis, availability of CYP2C19 genotype result, clopidogrel exposure, and established patient care. Patients with intracranial atherosclerosis, aneurysm, arteriovenous malformation, prior ischemic stroke, or observation time <1 month were excluded. Dual antiplatelet therapy patients were included. Patients with carotid endarterectomy or stenting were analyzed in a separate subgroup. Time-to-event analysis using Cox regression was conducted to model ischemic stroke events based on CYP2C19 loss-of-function allele and adjusted with the most predictive covariates from univariate analysis. Covariates included age, gender, race, length of aspirin, length of concurrent antiplatelet/anticoagulant treatment, diabetes, coagulopathy, hypertension, heart disease, atrial fibrillation, and lipid disorder. A total of 1110 patients met selection criteria for medical therapy cohort (median age 68 [interquartile range (IQR) 60-75] years, 64.9% male, 91.9% Caucasian). Median study period was 2.8 [0.8-5.3] years. A total of 47 patients (4.2%) had an ischemic stroke event during study period. CYP2C19 loss-of-function allele was strongly associated with ischemic stroke events (one allele: HR 2.3, 95% CI 1.1-4.7, p=0.020; two alleles: HR 10.2, 95% CI 2.8-36.8, p<0.001) after adjustment. For asymptomatic carotid stenosis patients receiving clopidogrel to prevent ischemic stroke, CYP2C19 loss-of-function allele is associated with 2- to 10-fold increased risk of ischemic stroke. CYP2C19 genotype may be considered when selecting antiplatelet therapy for stroke prophylaxis in non-procedural, asymptomatic carotid stenosis.
本研究旨在评估 CYP2C19 基因型对无症状性颅外颈动脉狭窄患者氯吡格雷治疗期间发生缺血性卒中的影响。研究使用去标识化的电子健康记录,通过颈动脉狭窄的行政代码、CYP2C19 基因型结果的可用性、氯吡格雷的暴露情况以及既定的患者护理,选择回顾性队列患者。排除颅内动脉粥样硬化、动脉瘤、动静脉畸形、既往缺血性卒中或观察时间<1 个月的患者。入选双联抗血小板治疗患者。对颈动脉内膜切除术或支架置入术患者进行亚组分析。使用 Cox 回归进行时间事件分析,以基于 CYP2C19 功能丧失等位基因的模型构建缺血性卒中事件,并使用单变量分析中最具预测性的协变量进行调整。协变量包括年龄、性别、种族、阿司匹林使用时间、同时使用抗血小板/抗凝药物治疗的时间、糖尿病、凝血障碍、高血压、心脏病、心房颤动和脂质紊乱。共有 1110 名患者符合药物治疗队列的入选标准(中位年龄 68 [四分位距 60-75] 岁,64.9%为男性,91.9%为白种人)。中位研究时间为 2.8 [0.8-5.3] 年。研究期间共有 47 名患者(4.2%)发生缺血性卒中事件。CYP2C19 功能丧失等位基因与缺血性卒中事件密切相关(一个等位基因:HR 2.3,95%CI 1.1-4.7,p=0.020;两个等位基因:HR 10.2,95%CI 2.8-36.8,p<0.001),调整后差异有统计学意义。对于接受氯吡格雷预防缺血性卒中的无症状性颈动脉狭窄患者,CYP2C19 功能丧失等位基因与缺血性卒中的风险增加 2-10 倍相关。在非手术、无症状性颈动脉狭窄患者中选择抗血小板治疗预防卒中时,可考虑 CYP2C19 基因型。